Vidac Pharma is advancing a first-in-class portfolio in dermatology and oncology based on modulation of cancer cell metabolism. The Company’s programs span late-stage topical development and preclinical systemic candidates, supported by a robust intellectual property portfolio.
First-in-Class Portfolio in Dermatology and Oncology
VDA-1102 - Actinic Keratosis (AK)
Current Phase: Phase 2B* (Advanced AK)
Trial Location: Germany
Status: Ongoing
VDA-1102 is a topical small-molecule candidate designed to target abnormal metabolic processes in malignant cutaneous cells. Unlike conventional field therapies, VDA-1102 is intended to selectively affect diseased tissue while minimizing impact on surrounding healthy skin.
Following analysis of earlier Phase 2B data, Vidac has initiated a second Phase 2B* clinical trial focused on patients with highly proliferative, advanced AK lesions, which represent a population at increased risk of progression to invasive disease.
Study overview:
- Conducted in Germany
- CRO: Forschungsdock
- Lead Investigator: Prof. Thomas Dirschka (CentroDerm)
- Primary objectives include evaluation of lesion clearance and disease progression parameters
VDA-1102 - Cutaneous T-Cell Lymphoma (CTCL)
Current Status: Phase 2 Successfully Concluded
Next Step: Preparation for Pivotal Phase 2–3
Classification: Orphan Disease
Vidac has successfully completed its Phase 2 clinical study evaluating VDA-1102 topical ointment in patients with early-stage CTCL (mycosis fungoides). The study was conducted under the direction of Prof. Emilia Hodak and demonstrated a favorable safety and tolerability profile togethe with clinically meaningful activity.
Based on the final clinical report submitted to the relevant regulatory authorities, the results support advancement to a pivotal Phase 2–3 clinical trial, representing the next step toward potential product registration.
Current Phase: Advanced Preclinical / IND-Enabling
VDA-1275 is Vidac’s next-generation systemic small-molecule candidate for the treatment of solid tumors. While chemically distinct from VDA-1102, it targets the same underlying metabolic checkpoint involving hexokinase-2 (HK2) and mitochondrial VDAC channels.
Preclinical studies have demonstrated activity across multiple tumor models, and Vidac is advancing VDA-1275 through IND-enabling development as a potential systemic oncology therapy.
Scientific Background
Vidac’s candidates are designed to modulate the HK2 metabolic checkpoint, a central regulator of cancer cell metabolism. By disrupting the interaction between HK2 and mitochondrial VDAC channels, the approach aims to interfere with aberrant glycolysis while influencing cellular survival pathways and the tumor microenvironment.